Trial Profile
Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m2 in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Oct 2022
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Docetaxel; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms FIRSTANA
- Sponsors Sanofi
- 13 Sep 2022 Results assessing the PSA decline kinetics using mathematical modelling, and investigating the prognostic/predictive value of kinetic parameters, presented at the 47th European Society for Medical Oncology Congress
- 01 Jul 2021 Results of post-hoc analysis of two studies (PROSELICA (NCT01308580) and FIRSTANA (NCT01308567)) assessing patient-reported health-related quality of life (HRQL), published in the Oncologist.
- 04 Jun 2019 Results assessing cell-free DNA as a biomarker for taxane response by using data from two studies (PROSELICA and FIRSTANA) presented at the 55th Annual Meeting of the American Society of Clinical Oncology